Heart and blood vessel outcomes after aortic valve replacement linked to GLP-1 receptor agonist treatment

GLP-1 receptor agonists are associated with a reduction in major adverse cardiovascular events among patients with diabetes, overweight, and obesity.

• The potential benefits of GLP-1 receptor agonists for patients undergoing aortic valve replacement remain unclear.
• There is a need to investigate whether these treatments could influence cardiovascular outcomes specifically in patients with severe aortic stenosis.
• The study focuses on understanding the association between GLP-1 receptor agonist treatment and cardiovascular outcomes post-AVR.

Simplified